MARKSANS
FAIRLY_VALUEDMarksans Pharma Limited
Healthcare · NSE
↓ 1.1% vs fair value
52W Low
₹155
+7.5% from low
52W High
₹271
-38.4% from high
Valuation Gauge
Current Price
₹167
Fair Value
₹165
Fair Value Analysis
₹165
Based on free cash flow projections and balance sheet strength analysis and earnings growth potential for Healthcare sector companies | CAUTION: ROCE declining (latest 19.0%) — returns on capital are falling; verify this isn't a value trap.
Cash Flow Analysis
40% weight
Balance Sheet Value
20% weight
Growth Valuation
40% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Healthy
Profitability
ROE of 13.5% is acceptable for Healthcare sector (benchmark: 15%)
Debt & Leverage
D/E ratio of 0.1x is well within the Healthcare sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 21.1x trades at a 87% discount to Healthcare sector median (160x) — attractively valued
Cash Flow
FCF margin of 1.3% — very thin despite positive FCF (₹34 Cr)
Earnings Growth
5yr EPS CAGR of 27.3% is in line with the Healthcare sector average of 18.7%
Dividend
Dividend yield of 0.5% is symbolic — low but positive
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
2.1%
Free cash flow / market cap
Revenue Growth (YoY)
+10.6%
Year-on-year revenue change
Profit Growth (YoY)
+8.6%
Year-on-year PAT change
Operating Cash Flow
₹207 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹8
P/E Ratio
21.1x
P/B Ratio
2.9x
ROE
13.5%
ROCE
18.7%
Debt / Equity
0.12x
Beta
1.03
Div Yield
0.5%
FCF (Cr)
₹34 Cr
Revenue (Cr)
₹2,614 Cr
EPS Growth 5Y
27.3%
Mkt Cap (Cr)
₹7,620 Cr
52W High
₹270.7
52W Low
₹155
Book Value/Share
₹59
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹2.8K Cr | ₹532 Cr | 19.0% | ₹362 Cr | ₹7.96 |
| 2025-03-31 | ₹2.6K Cr | ₹529 Cr | 20.0% | ₹383 Cr | ₹8.40 |
| 2024-03-31 | ₹2.2K Cr | ₹459 Cr | 21.0% | ₹315 Cr | ₹6.92 |
| 2023-03-31 | ₹1.9K Cr | ₹340 Cr | 18.0% | ₹265 Cr | ₹5.88 |
| 2022-03-31 | ₹1.5K Cr | ₹259 Cr | 17.0% | ₹187 Cr | ₹4.51 |
| 2021-03-31 | ₹1.4K Cr | ₹340 Cr | 25.0% | ₹239 Cr | ₹5.76 |
| 2020-03-31 | ₹1.1K Cr | ₹192 Cr | 17.0% | ₹121 Cr | ₹2.95 |
| 2019-03-31 | ₹1.0K Cr | ₹132 Cr | 13.0% | ₹80 Cr | ₹1.87 |
| 2018-03-31 | ₹913 Cr | ₹78 Cr | 9.0% | ₹36 Cr | ₹0.80 |
| 2017-03-31 | ₹767 Cr | ₹45 Cr | 6.0% | ₹11 Cr | ₹0.22 |
| 2016-03-31 | ₹893 Cr | ₹136 Cr | 15.0% | ₹83 Cr | ₹1.92 |
| 2015-03-31 | ₹797 Cr | ₹185 Cr | 23.0% | ₹112 Cr | ₹2.67 |
| 2014-03-31 | ₹630 Cr | ₹118 Cr | 19.0% | ₹74 Cr | ₹1.87 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Healthcare| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Alpa Laboratories Limited | ₹62.1 | ₹198.5 | +68.7% | 9.4 | 13.4% | FAIRLY_VALUED |
Aster DM Healthcare | ₹670 | ₹1,585.8 | +57.8% | 103.2 | 7.9% | UNDERVALUED |
Unichem Laboratories Limited | ₹300 | ₹592.5 | +49.4% | 7.1 | 12.1% | FAIRLY_VALUED |
Dishman Carbogen Amcis Limited | ₹147.6 | ₹281.2 | +47.5% | 19.5 | 1.9% | FAIRLY_VALUED |
Vimta Labs Limited | ₹414.8 | ₹722.6 | +42.6% | 24.6 | 16.6% | UNDERVALUED |
Morepen Laboratories Limited | ₹38.4 | ₹52.8 | +27.2% | 21 | 10.8% | FAIRLY_VALUED |
Indraprastha Medical Corporation Limited | ₹410 | ₹462.6 | +11.4% | 20 | 20.6% | FAIRLY_VALUED |
Kronox Lab Sciences Limited | ₹133 | ₹130.7 | -1.8% | 16.9 | 24.8% | FAIRLY_VALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant